Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, announced the positive results of a Phase 3 clinical trial conducted by its license partner, Ascletis Bioscience Co. Ltd. in China, for the treatment of moderate to severe acne vulgaris. The trial evaluated the oral small molecule fatty acid synthase (FASN) inhibitor, denifanstat, which met all primary and secondary endpoints versus a placebo and was well tolerated by participants. This development marks an advancement in acne treatment, introducing a novel mechanism of action through FASN inhibition. Additionally, Sagimet has initiated a Phase 1 clinical trial in the United States for a second FASN inhibitor, TVB-3567, targeting acne treatment. The positive outcomes from the trial underscore the potential of FASN inhibition as a therapeutic approach for acne.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.